Menu
Apply

Spinal Muscular Atrophy

Apply

Co-Pay Relief Program Fund Notices

Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!

Get Notified


Status
Open
Fund Type

Co-pay, Co-Insurance & Deductible

Maximum Award Level

$4,500 Per Year

Eligibility Requirements
  • Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
  • Insurance Requirements All Insurance Types
  • Must reside and receive treatment in the United States.

About Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic disorder in which nerve cells in the spinal cord and brain stem degenerate, causing progressive muscle and wasting. The protein called SMN (survival of motor neuron) is found on both copies of the SMN1 gene. SMA is characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles).Weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). The muscle weakness usually worsens with age. The SMN2 gene is found throughout the body, but has the highest levels in the spinal cord.

There are three types of SMA where symptoms first appear during infancy and childhood, type I SMA, also called Werdnig-Hoffman disease, is apparent by age 6 months accounts for more than half of new cases; type II (intermediate) SMA typically develops between age 3 and 15 months; type III SMA, also called Wohlfart-Kugelberg-Welander disease, begins between age 15 months and 19 years and worsens slowly. Type IV SMA first appears between the ages of 30 and 60 years old. Other names for this condition includes: 5q SMA, proximal SMA, SMA, SMA-associated SMA, spinal amyotrophies, spinal amyotrophy, spinal muscle degeneration, spinal muscle wasting, and infantile onset.

Spinal Muscular Atrophy Resources
Medication & Financial Assistance Resources
The Patient Advocate Foundation's (PAF) Co-Pay Relief (CPR) Program does not review the information contained on the website links provided for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions as outlined on the accessed websites. PAF Co-Pay Relief Program makes no representation as to the accuracy or any other aspect of the information contained on any website accessed from the CPR website, nor does PAF Co-Pay Relief Program necessarily endorse the website information provided. The information presented on the PAF Co-Pay Relief website is provided for general information only and is not intended as a substitute for medical care. Please talk with your healthcare provider about any information you acquire from this or any other website accessed through the PAF Co-Pay Relief program website.
Apply